304 related articles for article (PubMed ID: 34533681)
1. Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer.
Van Belle H; Hurvitz SA; Gilbar PJ; Wildiers H
Breast Cancer Res Treat; 2021 Dec; 190(3):357-372. PubMed ID: 34533681
[TBL] [Abstract][Full Text] [Related]
2. Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo-adjuvant treatment for Her2 positive breast cancer patients and impact of colony-stimulating factor prophylaxis.
Bayo J; Aviñó V; Toscano F; Jiménez F
Breast J; 2018 Jul; 24(4):462-467. PubMed ID: 29205665
[TBL] [Abstract][Full Text] [Related]
3. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
Do T; Medhekar R; Bhat R; Chen H; Niravath P; Trivedi MV
Breast Cancer Res Treat; 2015 Oct; 153(3):591-7. PubMed ID: 26337685
[TBL] [Abstract][Full Text] [Related]
4. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.
Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Okada M
Support Care Cancer; 2021 Jul; 29(7):3507-3512. PubMed ID: 33146835
[TBL] [Abstract][Full Text] [Related]
5. A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens.
Zardawi SJ; Nordman I; Zdenkowski N
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1266. PubMed ID: 32761893
[TBL] [Abstract][Full Text] [Related]
6. Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy.
Blayney DW; Kuderer NM; Cummings Joyner AK; Jarvis J; Nunag D; Wells J; Huang L; Mohanlal R; Lyman GH
J Natl Compr Canc Netw; 2023 Sep; 21(9):945-950.e16. PubMed ID: 37673111
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
[TBL] [Abstract][Full Text] [Related]
8. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.
Gerlier L; Lamotte M; Awada A; Bosly A; Bries G; Cocquyt V; Focan C; Henry S; Lalami Y; Machiels JP; Mebis J; Straetmans N; Verhoeven D; Somers L
BMC Cancer; 2010 Nov; 10():642. PubMed ID: 21092320
[TBL] [Abstract][Full Text] [Related]
9. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
Skedgel C; Rayson D; Younis T
Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
[TBL] [Abstract][Full Text] [Related]
10. Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer.
Zekri J; Nawaz A; Rasool H; Ahmad I; Abdel Rahman H; Dada R; Abdelghany EM; Farag K; Ibrahim RB; Deibas MY; Kamel MK; Allithy A
J Oncol Pharm Pract; 2022 Dec; 28(8):1681-1686. PubMed ID: 34342555
[TBL] [Abstract][Full Text] [Related]
11. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.
Agiro A; Ma Q; Acheson AK; Wu SJ; Patt DA; Barron JJ; Malin JL; Rosenberg A; Schilsky RL; Lyman GH
J Clin Oncol; 2016 Nov; 34(32):3872-3879. PubMed ID: 27646945
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
Sakurada T; Bando S; Zamami Y; Takechi K; Chuma M; Goda M; Kirino Y; Nakamura T; Teraoka K; Morimoto M; Tangoku A; Ishizawa K
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1107-1114. PubMed ID: 31502114
[TBL] [Abstract][Full Text] [Related]
13. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.
Younis T; Rayson D; Jovanovic S; Skedgel C
Breast Cancer Res Treat; 2016 Oct; 159(3):425-32. PubMed ID: 27572552
[TBL] [Abstract][Full Text] [Related]
15. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
16. Effect of Secondary Prophylactic G-CSF on the Occurrence of Febrile Neutropenia in Breast Cancer.
Suzuki K; Sasada S; Kimura Y; Emi A; Kadoya T; Okada M
Anticancer Res; 2022 Dec; 42(12):5945-5949. PubMed ID: 36456134
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles.
van Dooijeweert C; van der Wall E; Baas IO
Neth J Med; 2019 Dec; 77(9):310-316. PubMed ID: 31814585
[TBL] [Abstract][Full Text] [Related]
18. Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.
Fernandes R; Mazzarello S; Stober C; Vandermeer L; Dudani S; Ibrahim MF; Majeed H; Perdrizet K; Shorr R; Hutton B; Fergusson D; Clemons M
Breast Cancer Res Treat; 2017 Jan; 161(1):1-10. PubMed ID: 27783280
[TBL] [Abstract][Full Text] [Related]
19. A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
Clemons M; Fergusson D; Joy AA; Thavorn K; Meza-Junco J; Hiller JP; Mackey J; Ng T; Zhu X; Ibrahim MFK; Sienkiewicz M; Saunders D; Vandermeer L; Pond G; Basulaiman B; Awan A; Pitre L; Nixon NA; Hutton B; Hilton JF;
Breast; 2021 Aug; 58():42-49. PubMed ID: 33901921
[TBL] [Abstract][Full Text] [Related]
20. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
